Table 3. Patient characteristics in the AVOID group and the DELAY group.
| AVOID (N=13) | DELAY (N=22) | P value | |
|---|---|---|---|
| Median age (range) | 57 | 42.5 | 0.47 |
| Sex | |||
| Male/Female | 9/4 | 12/10 | 0.49 |
| Disease | |||
| AML | 6 | 12 | 0.39 |
| ALL | 4 | 2 | |
| MDS/MPD | 2 | 2 | |
| ML/MM | 1 | 3 | |
| sAA | 0 | 3 | |
| Disease status | |||
| CR1 | 3 | 7 | 0.48 |
| CR2-4 | 3 | 8 | |
| relapse/refractory | 4 | 2 | |
| primary therapy | 3 | 5 | |
| Performance status | |||
| 0/1 | 13 | 22 | - |
| 2/4 | 0 | 0 | |
| Conditioning regimen | |||
| MAC | 5 | 14 | 0.18 |
| RIC | 8 | 8 | |
| TBI regimen | |||
| Yes | 9 | 16 | 1.00 |
| No | 4 | 6 | |
| Use of ATG | |||
| Yes | 0 | 3 | 0.28 |
| No | 13 | 19 | |
| Recipient / Donor CMV status | |||
| Pos. / Pos. | 8 | 13 | 1.00 |
| Pos. / Neg. | 5 | 8 | |
| Neg. / Pos. | 0 | 1 | |
| Acute GVHD | |||
| Grade 0-1 | 8 | 10 | 0.49 |
| Grade 2-4 | 5 | 12 | |
| Use of steroids within 100 days after HSCT | |||
| Yes | 4 | 15 | 0.043 |
| No | 9 | 7 | |
AML: acute myeloid leukemia, ALL: acute lymphoblastic lymphoma, MDS: myelodysplastic syndrome, MPD: myeloproliferative disease, ML: malignant lymphoma, MM: multiple myeloma, sAA: severe aplastic anemia, CR: complete response, MAC: myeloablative conditioning, RIC: reduced intensity conditioning, ATG: antithymoglobulin, GVHD: graft versus host disease, Pos: positive, Neg: negative